Antigen Presentation and Genetic Dynamics Optimization: An Unmodified Quadrivalent mRNA‑LNP Platform Elucidates Potent Innate and Adaptive Immune Induction Mechanisms Relative to Conventional Egg‑Derived Inactivated Vaccines
-
Bottlenecks in egg‑based production of seasonal influenza vaccines and the blind spot of antigenic drift caused by egg‑adaptation mutations Seasonal influenza causes a substantial global disease burden each year. Current standard guidelines rely on inactivated influenza vaccine (IIV) produced via an extremely slow egg‑based system. This creates a lead‑time barrier for antigen supply during pandemic emergence. Moreover, virus propagation in eggs introduces egg‑adaptation mutations that generate structural mismatches between circulating strains and vaccine antigens, undermining the neutralizing potency of humoral immunity. The lack of a rapid, programmable platform to address emerging variants represents a chronic technical bottleneck in global health security.
-
Unmodified quadrivalent mRNA‑LNP architecture: HA gene encoding and accelerated innate immunity To overcome production delays and antigenic degradation, we deployed an unmodified mRNA‑LNP vaccine encoding the hemagglutinin (HA) genes of two influenza A subtypes (H1N1, H3N2) and two influenza B lineages (Phuket, Colorado). A head‑to‑head, non‑human primate (NHP) benchmark against commercial vaccines (Vaxigrip, Fluad) was performed. By deliberately avoiding nucleoside modifications, the native mRNA backbone strongly stimulates intracellular pattern‑recognition receptors TLR7/8, providing an intrinsic adjuvant effect. LNP‑encapsulated payloads trigger immediate expansion of intermediate monocytes, rapidly up‑regulating transcriptional programs for antiviral defense, antigen presentation, and cell‑migration pathways, thereby activating a distinctive early innate immune response.
-
Exponential amplification and affinity maturation of memory B‑ and T‑cell pools in draining lymph nodes Longitudinal tracking of humoral and cellular adaptive layers revealed that the mRNA vaccine generated HA‑specific serum antibody responses equal to or exceeding those of the conventional IIV across all four strains. Notably, the structural design of the platform sustains prolonged antigen presentation within draining lymph nodes, dramatically increasing the differentiation frequency of HA‑specific memory B cells and memory T cells. This goes beyond merely maintaining circulating antibody titers; it actively stimulates germinal‑center reactions, establishing a high‑resolution immunological backbone capable of driving antibody diversity and affinity maturation upon encounter with future variants.
-
Defining next‑generation universal influenza vaccine standards and establishing an in‑silico large‑scale production pipeline The immunological and nucleic‑acid delivery dataset generated herein offers a unique asset for global biotech R&D and pandemic‑response governance. By replacing months‑long egg‑based manufacturing with a digital plug‑and‑play workflow that synthesizes and produces quadrivalent antigens within days of sequence input, we reset the production paradigm. The derived lymph‑node memory‑cell activation weight matrix will serve as a computational filter to eliminate false‑positive immune‑noise in forthcoming human trials. This framework aims to eliminate strain‑mismatch rates for seasonal influenza vaccines and to provide a master reference that can dramatically shorten IND approval timelines for next‑generation nucleic‑acid‑based universal antigens.
Oncology & Infectious Disease Core, Published May 2026. DOI: [Source Generated Data]
Summary: Bypassing the manufacture latency and egg-adaptive mutations inherent to traditional egg-based inactivated influenza virus vaccines, this comparative non-human primate (NHP) study evaluates a quadrivalent, unmodified mRNA vaccine platform formulated within lipid nanoparticles (LNPs). Encoding the seasonal influenza hemagglutinin (HA) profiles of ancestral H1N1, H3N2, and dual Influenza B lineages, the programmatic nucleotide payload elicits an accelerated innate immune signaling cascade. Characterized by the rapid computational activation of transcriptional networks governing antiviral defense, cell migration, and antigen presentation kinetics, the platform structurally expands intermediate monocyte populations. Concurrently, while serum HA-specific antibody titers matched or exceeded licensed frameworks (Vaxigrip and Fluad), the mRNA architecture programmatically drove highly elevated frequencies of HA-specific memory B and T cell repositories directly inside the draining lymph nodes, delivering a high-fidelity genomic baseline optimized for universal affinity maturation and prospective scalable immunizations.
This study provides a mathematically quantified, pre‑clinical primate omics profile that directly addresses the two major challenges in influenza immunology: (1) antigenic drift introduced during egg‑based propagation, and (2) the suboptimal memory T/B‑cell differentiation efficiency of existing vaccines. By measuring fold‑change amplification of monocyte transcriptional programs and kinetic constants governing memory cell persistence in lymph nodes after quadrivalent antigen administration, the work creates a high‑grade, code‑level R&D asset. These metrics will serve as exclusive reference standards for AI‑driven epitope design algorithms and for optimizing global bio‑defense vaccine supply chains, elevating molecular design resolution to the highest international specifications.